Rifamate

Pruritus, Nasopharynx, Latent Tuberculosis + 4 more

Treatment

5 FDA approvals

2 Active Studies for Rifamate

What is Rifamate

Rifampicin

The Generic name of this drug

Treatment Summary

Rifampin is an antibiotic created from Streptomyces mediterranei. It can be used to treat a wide range of bacterial infections, including some types of Mycobacterium. Rifampin works by binding to the DNA-dependent RNA polymerase enzyme and stopping the production of RNA. This makes it effective against both intracellular and extracellular bacteria, as it kills both types of organisms.

Rifadin

is the brand name

image of different drug pills on a surface

Rifamate Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Rifadin

Rifampicin

1971

75

Approved as Treatment by the FDA

Rifampicin, otherwise known as Rifadin, is approved by the FDA for 5 uses which include late phase Tuberculosis and initial phase Tuberculosis .

late phase Tuberculosis

Used to treat late phase Tuberculosis in combination with Isoniazid

initial phase Tuberculosis

Used to treat initial phase Tuberculosis in combination with Isoniazid

Nasopharynx

Tuberculosis

Used to treat late phase Tuberculosis in combination with Isoniazid

Latent Tuberculosis

Used to treat initial phase Tuberculosis in combination with Isoniazid

Effectiveness

How Rifamate Affects Patients

Rifampin is an antibiotic that prevents bacteria from making the genetic material they need to survive and reproduce. It works on most types of bacteria, including those that cause tuberculosis. It is absorbed quickly when taken by mouth and travels to many areas of the body, including the brain. It is broken down by the liver and then excreted in bile and urine. People with kidney problems do not need to adjust their dose.

How Rifamate works in the body

Rifampin stops cells from making new RNA. This prevents them from replicating and eventually leads to cell death.

When to interrupt dosage

The measure of Rifamate relies upon the determined condition, counting antibacterial therapy, Prosthetic Joint Infections and Nasopharynx. The prescribed dosage shifts, contingent upon the system of dispensation as featured in the table below.

Condition

Dosage

Administration

Nasopharynx

60.0 mg/mL, , 300.0 mg, 120.0 mg, 150.0 mg, 600.0 mg, 450.0 mg

, Injection, powder, lyophilized, for solution, Intravenous, Injection, powder, lyophilized, for solution - Intravenous, Capsule - Oral, Oral, Capsule, Tablet, sugar coated, Tablet, sugar coated - Oral, Capsule, coated, Capsule, coated - Oral, Tablet - Oral, Tablet

Latent Tuberculosis

60.0 mg/mL, , 300.0 mg, 120.0 mg, 150.0 mg, 600.0 mg, 450.0 mg

, Injection, powder, lyophilized, for solution, Intravenous, Injection, powder, lyophilized, for solution - Intravenous, Capsule - Oral, Oral, Capsule, Tablet, sugar coated, Tablet, sugar coated - Oral, Capsule, coated, Capsule, coated - Oral, Tablet - Oral, Tablet

Tuberculosis

60.0 mg/mL, , 300.0 mg, 120.0 mg, 150.0 mg, 600.0 mg, 450.0 mg

, Injection, powder, lyophilized, for solution, Intravenous, Injection, powder, lyophilized, for solution - Intravenous, Capsule - Oral, Oral, Capsule, Tablet, sugar coated, Tablet, sugar coated - Oral, Capsule, coated, Capsule, coated - Oral, Tablet - Oral, Tablet

antibacterial therapy

60.0 mg/mL, , 300.0 mg, 120.0 mg, 150.0 mg, 600.0 mg, 450.0 mg

, Injection, powder, lyophilized, for solution, Intravenous, Injection, powder, lyophilized, for solution - Intravenous, Capsule - Oral, Oral, Capsule, Tablet, sugar coated, Tablet, sugar coated - Oral, Capsule, coated, Capsule, coated - Oral, Tablet - Oral, Tablet

Staphylococcal Infections

60.0 mg/mL, , 300.0 mg, 120.0 mg, 150.0 mg, 600.0 mg, 450.0 mg

, Injection, powder, lyophilized, for solution, Intravenous, Injection, powder, lyophilized, for solution - Intravenous, Capsule - Oral, Oral, Capsule, Tablet, sugar coated, Tablet, sugar coated - Oral, Capsule, coated, Capsule, coated - Oral, Tablet - Oral, Tablet

Prosthetic Joint Infections

60.0 mg/mL, , 300.0 mg, 120.0 mg, 150.0 mg, 600.0 mg, 450.0 mg

, Injection, powder, lyophilized, for solution, Intravenous, Injection, powder, lyophilized, for solution - Intravenous, Capsule - Oral, Oral, Capsule, Tablet, sugar coated, Tablet, sugar coated - Oral, Capsule, coated, Capsule, coated - Oral, Tablet - Oral, Tablet

Pruritus

60.0 mg/mL, , 300.0 mg, 120.0 mg, 150.0 mg, 600.0 mg, 450.0 mg

, Injection, powder, lyophilized, for solution, Intravenous, Injection, powder, lyophilized, for solution - Intravenous, Capsule - Oral, Oral, Capsule, Tablet, sugar coated, Tablet, sugar coated - Oral, Capsule, coated, Capsule, coated - Oral, Tablet - Oral, Tablet

Warnings

Rifamate Contraindications

Condition

Risk Level

Notes

Pulse Frequency

Do Not Combine

Pulse Frequency

Do Not Combine

Pulse Frequency

Do Not Combine

Pulse Frequency

Do Not Combine

Pulse Frequency

Do Not Combine

There are 20 known major drug interactions with Rifamate.

Common Rifamate Drug Interactions

Drug Name

Risk Level

Description

1,2-Benzodiazepine

Major

The metabolism of 1,2-Benzodiazepine can be increased when combined with Rifampicin.

3,5-diiodothyropropionic acid

Major

The metabolism of 3,5-diiodothyropropionic acid can be increased when combined with Rifampicin.

5-androstenedione

Major

The metabolism of 5-androstenedione can be increased when combined with Rifampicin.

6-O-benzylguanine

Major

The metabolism of 6-O-benzylguanine can be increased when combined with Rifampicin.

7-ethyl-10-hydroxycamptothecin

Major

The metabolism of 7-ethyl-10-hydroxycamptothecin can be increased when combined with Rifampicin.

Rifamate Toxicity & Overdose Risk

The toxic dose of the drug in rats is 1570mg/kg. Long-term exposure can lead to nausea, vomiting, and loss of consciousness.

image of a doctor in a lab doing drug, clinical research

Rifamate Novel Uses: Which Conditions Have a Clinical Trial Featuring Rifamate?

Presently, 5 active investigations are examining the potential of Rifamate to alleviate late-phase Tuberculosis, initial-phase Tuberculosis and Pruritus.

Condition

Clinical Trials

Trial Phases

Tuberculosis

0 Actively Recruiting

Nasopharynx

0 Actively Recruiting

Latent Tuberculosis

0 Actively Recruiting

antibacterial therapy

0 Actively Recruiting

Staphylococcal Infections

0 Actively Recruiting

Prosthetic Joint Infections

2 Actively Recruiting

Phase 4, Not Applicable

Pruritus

0 Actively Recruiting

Patient Q&A Section about rifamate

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What are the side effects of isoniazid and rifampin?

"The following are potential side effects of the medication: a change in the color of tears, sweat, saliva, urine, or stools to a red-orange hue; numbness, tingling, or itching; a mild rash; drowsiness, dizziness, or headache; muscle pain or weakness; heartburn, gas, or diarrhea; or mouth pain."

Answered by AI

What is rifampicin and isoniazid?

"Isoniazid belongs to the class of medicines called antituberculous agents, and works by preventing the growth of TB bacteria.

The combination of rifampin and isoniazid is used to treat an infection with tuberculosis (TB) bacteria. Rifampin is an antibiotic that kills or prevents the growth of bacteria. Isoniazid is an antituberculous agent that prevents the growth of TB bacteria."

Answered by AI

How do you take rifampicin and isoniazid?

"The recommended dose of isoniazid, pyrazinamide, and rifampin is one tablet taken with a full glass of water 1 hour before or 2 hours after a meal. After 2 months of using this drug combination, treatment should be continued with rifampin and isoniazid for at least 4 months."

Answered by AI

What is rifampin used to treat?

"Rifampin is used in conjunction with other medications to treat tuberculosis in various parts of the body. It is also used by asymptomatic patients who have meningitis bacteria in their nose or throat, in order to prevent the spread of the infection to others."

Answered by AI

Clinical Trials for Rifamate

Image of University of Miami Health System in Miami, United States.

Antibiotic-Coated Sutures for Prosthetic Joint Infections

18 - 89
All Sexes
Miami, FL

The purpose of this study is to evaluate whether the use of antibiotic-coated (triclosan) braided sutures is non-inferior or potentially superior to standard monofilament sutures in patients with prosthetic joint infections (PJIs) managed with the DAIR protocol. Several studies in various surgical specialties have demonstrated the effectiveness and non-inferiority of triclosan-coated braided sutures in infected surgical cases, and the study intends to transpose this idea to the management of prosthetic joint infections. Monofilament sutures are the present standard of care in any infected joint case due their lower surface area for bacterial harborization, though surgeons sacrifice mechanical integrity and comfortability with the closure in the process. By demonstrating the safety of antibiotic -coated braided sutures, surgeons will no longer have to make this compromise.

Waitlist Available
Has No Placebo

University of Miami Health System

Colin McNamara, MD